References
- Reslan L, Dalle S, Herveau S, et al. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma. 2014;55(1):188–190.
- Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031–2042.
- Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273.
- Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
- Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
- Hayama T, Miura K, Uchiike A, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39(2):380–385.
- Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159–170.e2.
- Van Der Kolk LE, Grillo-López AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807–811.
- National Clinical Guideline Centre (UK). Drug allergy: diagnosis and management of drug allergy in adults, children and young people. London: National Institute for Health and Care Excellence (UK); 2014; (NICE Clinical Guidelines, no. 183.) 7, measuring serum tryptase after suspected anaphylaxis. Available from: https://www.Ncbi.Nlm.Nih.Gov/books/nbk274147/
- Levin AS, Otani IM, Lax T, et al. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107–113.
- Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45.
- Roche. Australian product information. Gazyva® (obinutuzumab). Sydney, Australia: Roche Products Pty Limited; 2019.
- Chen LY, Shah R, Cwynarski K, et al. Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab. Br J Haematol. 2019;184(3):462–465.
- Crowley MP, McDonald V, Scully M. Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab. N Engl J Med. 2018;378(1):92–93.
- Hara T, Suzuki R, Ohno A, et al. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. Int J Hematol. 2020;111(4):585–590.
- Salomon-Perzyński A, Końska A, Zawirska D, et al. Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab-associated anaphylaxis. Pol Arch Intern Med. 2018;128(7–8):494–495.
- Pirich T, Zwickl-Traxler E, Pecherstorfer M, et al. Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies – a retrospective single center cohort study. Oncotarget. 2018;9(52):29944–29956.
- Ghione P, Joffe E, De Paola N, et al. Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab. J Clin Oncol. 2020;38(15 Suppl.):8062.